Food Noise, Alcohol Noise, Nicotine Noise — Are They the Same Signal?

The Patient Reports Came First

Before the clinical trials, there were the stories. Thousands of them, posted on Reddit, shared in Facebook groups, told to physicians who didn't quite know what to make of them.

People prescribed semaglutide for diabetes or weight loss began noticing changes that had nothing to do with food. A woman who'd had two glasses of wine every evening for fifteen years found she simply forgot to pour the first one. A pack-a-day smoker realized he hadn't bought cigarettes in a week — not because he was trying to quit, but because the pull just wasn't there. Someone else noticed their compulsive online shopping had stopped.

The common thread in these reports wasn't willpower. It was the absence of something — a persistent mental itch, a background hum of wanting, suddenly gone quiet. Patients who had experienced "food noise" recognized the feeling immediately. It was the same silence, just applied to a different craving.

This pattern caught the attention of researchers, including a team at Virginia Tech who analyzed social media posts and found systematic reductions in reported cravings across multiple substance categories among GLP-1 users. It wasn't random. It was too consistent, too widespread, and too specific to dismiss.

One Highway, Many Destinations

The brain has a reward system — a set of interconnected regions that evolved to drive us toward things essential for survival: food, water, social connection, sex. At the core of this system sits the mesolimbic dopamine pathway, connecting the ventral tegmental area (VTA) deep in the midbrain to the nucleus accumbens (NAc) in the forebrain, with additional projections to the prefrontal cortex, amygdala, and hippocampus.

When you eat something delicious, dopamine surges along this pathway. When you take a sip of alcohol, dopamine surges. When you inhale nicotine, dopamine surges. When a gambling addict hears the slot machine chime, dopamine surges. The specific triggers differ. The highway is the same.

This is the key insight: addiction is not a substance-specific disease. It is a reward-pathway disease. Different substances and behaviors hijack the same circuitry. They just have different on-ramps.

And GLP-1 receptors, it turns out, are distributed across virtually every major node of this circuitry.

What GLP-1 Activation Does at Each Node

Research published in 2025 in MDPI Clinical Sciences and PMC has mapped the specific effects of GLP-1 receptor activation across the reward circuit. The picture that emerges is of a system-wide modulator — not a blunt off-switch, but a volume knob.

In the VTA: GLP-1 receptor activation reduces the hedonic and reinforcing properties of rewarding substances. In animal models, direct administration of GLP-1 agonists to the VTA produces more potent suppression of motivated behavior than administration to any other single region. It decreases dopamine release into the nucleus accumbens, turning down the "wanting" signal at its source.

In the nucleus accumbens: GLP-1 receptor activation alters glutamate signaling in ways that promote negative energy balance — essentially recalibrating the set point for "enough." Recent research shows semaglutide suppresses alcohol-induced dopamine elevation in this region specifically.

During withdrawal: GLP-1 agonists act on the lateral septum, hypothalamus, and brainstem to mitigate negative affect and stress — the emotional states that typically drive relapse. This may reduce stress-induced reinstatement of substance-seeking behavior.

In short, GLP-1 activation doesn't just dampen the pleasure of consumption. It dampens the wanting beforehand, the reinforcement during, and the stress-driven relapse cycle afterward. And because it works on the shared highway rather than any single on-ramp, the effect applies across substances.

Why Semaglutide Works Better Than Older GLP-1 Drugs

This is an important detail. Exenatide, a first-generation GLP-1 agonist, showed some anti-addiction effects in animal studies but produced mixed results in human trials. A clinical trial of exenatide for alcohol use disorder was inconclusive.

Semaglutide appears fundamentally different, and the explanation likely comes down to brain access. Studies mapping where semaglutide activates neurons in the brain found that peripheral semaglutide administration did not show strong evidence of direct access to the midbrain VTA — unlike exenatide administered directly into the brain. Yet semaglutide still produces robust effects on reward behavior.

One interpretation: semaglutide may work through distributed neural pathways and brainstem circuits that project to reward regions, rather than through direct VTA penetration. A 2020 study in JCI Insight found that semaglutide activated neuronal pathways that overlapped with meal-termination circuits controlled by the parabrachial nucleus — a region involved in aversion and satiety signaling.

The practical takeaway: semaglutide's ability to influence reward processing may operate through multiple complementary mechanisms — vagal signaling, brainstem-to-forebrain projections, and hormonal crosstalk — creating a more robust anti-craving effect than older, simpler GLP-1 agonists.

The Unifying Theory

Here's the framework emerging from the research: "food noise," "alcohol noise," and "nicotine noise" are all manifestations of the same underlying process — tonic reward-seeking activity in the mesolimbic dopamine system. The brain's default setting is to generate a low-level hum of "go find something rewarding." For some people, that hum is louder than for others. Genetics, trauma, stress, and metabolic factors all influence the volume.

GLP-1 receptor agonists appear to turn down that hum at the circuit level. They don't eliminate pleasure — people on semaglutide still enjoy food, still enjoy a drink if they choose to have one. But the compulsive background chatter, the "I need this right now" signal that drives overconsumption, gets quieter across the board.

This is why patients report such similar experiences regardless of what their particular "noise" was about. It was always the same signal. The GLP-1 medication is acting on the same pathway.

What We Still Don't Know

This unifying framework is elegant, but it's still incomplete. Several critical questions remain open.

Not everyone on GLP-1 medications experiences reduced substance cravings. Why? Is it dose-dependent? Is it related to individual variations in GLP-1 receptor density or sensitivity? Do some people have reward circuitry that's less responsive to GLP-1 modulation?

The gut-brain axis adds another layer of complexity. GLP-1 is originally a gut hormone, secreted by intestinal L-cells after eating. The interplay between peripheral GLP-1 signaling (through vagal nerve activation) and central nervous system effects is still being untangled. It's possible that some of the anti-craving effects are mediated through the gut rather than — or in addition to — direct brain action.

And the big question: are these effects durable? If you stop taking a GLP-1 medication, does the noise come back? For weight, the answer seems to be yes — most patients regain some weight after discontinuation. Whether the same applies to substance cravings is unknown.